Ovarian cancer is cancer that affects the ovaries. According to the WHO, an estimated 2,38,700 women were diagnosed with ovarian cancer in 2012. The report analyzes the demand for ovarian cancer drugs, which would contribute to the growth of the market. It focuses on both generic and brand drugs that are used to treat ovarian cancer and their impact on the market.
The market is driven by the increasing incidence of ovarian cancer. The need for more effective treatment options is pushing growth of the market. While the market is dominated by generics such as paclitaxel and carboplatin, it is expected that drugs such as Bevacizumab (Avastin), Pazopanib (Votrient) would boost the growth of this market. Development of drugs with improved efficacy is a challenge for this market. The opportunity for this market lies in developing new drugs for treating ovarian cancer.
Global Ovarian Cancer Drugs Market Analysis by Drug
The drugs used to treat ovarian cancer include Paclitaxel, Cisplatin, Adriamycin PFS (Doxorubicin Hydrochloride), Carboplatin, Cyclophosphamide, Platinol (Cisplatin), Paraplatin (Carboplatin), Doxorubicin Hydrochloride Liposome, Evacet (Doxorubicin Hydrochloride Liposome), Cytoxan (Cyclophosphamide), Paraplat (Carboplatin), Taxol (Paclitaxel), Neosar (Cyclophosphamide), Gemcitabine Hydrochloride, Platinol-AQ (Cisplatin), Topotecan Hydrochloride, Gemzar (Gemcitabine Hydrochloride), Hycamtin (Topotecan Hydrochloride), Doxorubicin Hydrochloride, LipoDox (Doxorubicin Hydrochloride Liposome), Dox-SL (Doxorubicin Hydrochloride Liposome), Clafen (Cyclophosphamide), Adriamycin RDF (Doxorubicin Hydrochloride), DOXIL (Doxorubicin Hydrochloride Liposome) and others. Treatment for ovarian cancer mostly includes a combination of two drugs, usually a platinum compound (Cisplatin or carboplatin) and a taxane (Paclitaxel or docetaxel).
Global Ovarian Cancer Drugs Market Analysis by Geography
The market for ovarian cancer is segmented geographically into North America, Europe, Asia Pacific and LAMEA. North America is the major revenue generating market mainly due to the prevalence of ovarian cancer. According to the American cancer society, an estimated 21,980 women would be diagnosed with ovarian cancer in 2014 in the US. Europe is the second largest market as the incidence for ovarian cancer is high in Europe.
The companies include Roche, Amgen, Boehringer Ingelheim, GlaxoSmithKline, AstraZeneca and others. In Dec 2011, Roche received EU approval for it drug Avastin (bevacizumab) to be used in combination with carboplatin and paclitaxel as treatment for ovarian cancer.
High Level Analysis
Market analysis by porter’s five-force model shows that the bargaining power of the buyer is high in this market as the market is dominated by generic drugs and there are many suppliers producing the drugs. The threat of new entrants is moderate as the drugs for treating ovarian cancer are mainly generic and pharmaceutical companies can easily start producing the drugs. Intensity of rivalry is high in this market as competitors are numerous and the drugs are undifferentiated. Top impacting factors have been given to get a clearer understanding of the market.
In-depth analysis of the drugs in the market for treatment of ovarian cancer would help in understanding the capacity for growth in this market
The ovarian cancer drug market is segmented by drugs and geography.
SIMILAR MARKET STUDIES
Notes: Production, means the output of Bipolar Coagulation Forcep Revenue, means the sales value of Bipolar Coagulation Forcep This report studies Bipolar Coagulation Forcep in Global market, especially in North America, Europe, China, Japan, Southeast Asia and India, focuses on top manufacturers in global market, with production, price, revenue and market share for ...
November 2016 | $2900 | View Details >>
Summary Avery Dennison Corporation (Avery Dennison) undertakes the production of pressure-sensitive materials and a variety of tickets, tags, labels and other converted products. Its major products include pressure-sensitive labeling materials, which include binders, organizing systems, markers; and variety of converted products such as fasteners, tickets, tags, radio-frequency identification (RFID) inlays and ...
July 2016 | $250 | View Details >>
Chemotherapy Induced Myelosuppression - Pipeline Review, H1 2015 Summary Global Markets Directs, Chemotherapy Induced Myelosuppression - Pipeline Review, H1 2015, provides an overview of the Chemotherapy Induced Myelosuppressions therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Chemotherapy Induced Myelosuppression, complete with comparative analysis at various stages, therapeutics assessment by ...
March 2015 | $2000 | View Details >>
The United States Acute Lymphoblastic Leukemia Therapeutics Industry 2016 Market Research Report is a professional and in-depth study on the current state of the Acute Lymphoblastic Leukemia Therapeutics industry. The report provides a basic overview of the industry including definitions, classifications, applications and industry chain structure. The Acute Lymphoblastic Leukemia Therapeutics ...
September 2016 | $3800 | View Details >>
UPCOMING MARKET RESEARCH REPORTS
2017 © Copyright Big Market Research